We were born as a spin-off of the University of Torino and the Italian National Institute of Nuclear Physics (INFN) and were supported by the 2i3T Incubator in Turin, Italy.
In 2007, we started laying down the foundations of the company following the input of medical
researchers who were setting up a multicenter Clinical Trial based on the use of PET/CT for the
assessment of the therapy response in Hodgkin Lymphoma.
The first beta version of WIDEN was available for testing in 2008 and was used by 3 PET-based
Clinical Trials for handling the imaging and diagnosis-related workflow.
Following the success of the beta version, diXit was founded at the beginning of 2011. From then we have worked with public and private organizations worldwide to improve healthcare thanks to science and technology.
Our multi-disciplinary team is composed of leading experts and PhDs in the fields of oncology & haematology, medical physics, experimental physics, statistics, business development, brand building and management.
SCIENTIFIC VALUE — Since 2010, the Polish Lymphoma Research Group is an active user of Dixit and their WIDEN platform, that enabled us to start and carry out Observational Study on the role of very early interim PET results during ABVD chemotherapy of patients with Hodgkin Lymphoma. The study requires reviewing of all interim PET studies by the independent Panel of Reviewers. Such a panel, consisting of the Polish and Italian nuclear medicine specialists was established. All reviewers have the access to anonymized PET scans loaded to the WIDEN platform by local PET centers in Poland. The process requires some basic computer skills and is feasible for all even inexperienced users. It allows comparing the concordance between reviewers and identifying cases requiring further discussion Without WIDEN our study would never gain any scientific value.
Gdynia Oncology Center – Medical University of Gdansk – Poland
AN ESSENTIAL SUPPORT — The International Extranodal Lymphoma Study Group is using Dixit and the WIDEN platform in several ongoing international clinical trials, in which the timely central review of PET scans is a most critical step. The WIDEN software fully meets our needs and completely fulfills our expectations. WIDEN has become an essential support to our research programs.
IELSG Scientific Director and CEO – Switzerland
AN ESSENTIAL SUPPORT — Our department is using Dixit and the WIDEN platform in an ongoing international clinical trial, in which the timely central review of PET scans is a most critical step. The WIDEN software fully meets our needs and completely fulfills our expectations. WIDEN has become an essential support to our research programs.
Head of Nuclear Medicine Department – Santa Maria Nuova Hospital – Reggio Emilia, Italy